NCT02672475View on ClinicalTrials.gov

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

April 30, 2021

Study Completion Date

August 31, 2023

Conditions
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IV Breast CancerTriple-Negative Breast Carcinoma
Interventions
DRUG

Galunisertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

Trial Locations (1)

37232

Vanderbilt University/Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT02672475 - Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter